Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence (Heroin).
The main use of naltrexone is for the treatment of alcohol dependence.
Naltrexone was approved for the treatment of alcohol dependence in 1994, following publication of the first two randomized, controlled trials in 1992. Since then a number of studies have confirmed its efficacy in reducing frequency and severity of relapse to drinking.
The standard regimen is one 50 mg tablet per day.
Naltrexone has been shown to reduce relapse rates after abstinence in multiple clinical studies. Additionally there is evidence that naltrexone helps reduce heavy drinking when used in people who continue drinking while taking naltrexone.
Naltrexone can be given in a daily base or as implant for reducing the relapses.
Opioid dependence (Heroin)
Naltrexone helps patients overcome opioid addiction by blocking the drugs’ euphoric effects.
Naltrexone treats the physical dependence on opioids.
Naltrexone should not be started prior to several (typically 7-10) days of abstinence from opioids. This is due to the risk of acute opioid withdrawal if naltrexone is taken, as naltrexone will displace most opioids from their receptors.
A newer option is the naltrexone implant, which must be surgically inserted under the skin. The implant provides a sustained dose of naltrexone to the patient, thereby preventing the problems which may be associated with missing doses. It must be replaced every four months.
Veresies Clinic has an experience of doing more than 200 implants for alcohol and opioid addiction with high percent of successful results.
For more information please contact : +357 99 659 659